Authorized purpose: ClearRead CT is a post-processing adjunct for detecting pulmonary nodules on chest CT in an asymptomatic population; it generates a secondary vessel-suppressed lung CT with CADe marks and region descriptors and must be reviewed with the original CT series.
Clinical role
Post-processing support for pulmonary-nodule detection during review of chest CT examinations.
Images and patients
CT/CTA · Chest/lungs
Key limitation
Keep in mind: ClearRead CT is an adjunct and must not be used without the original CT series. The cleared indication is for an asymptomatic population and requires both lungs in the field of view; radiologist judgment remains required.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: ClearRead CT is a post-processing adjunct for detecting pulmonary nodules on chest CT in an asymptomatic population; it generates a secondary vessel-suppressed lung CT with CADe marks and region descriptors and must be reviewed with the original CT series.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/lungs Input: Previously acquired chest CT studies with both lungs in the field of view.
Who uses it?Intended users: Radiologists reviewing CT examinations of the chest.
What does the software produce?Output: A secondary vessel-suppressed lung CT with CADe marks and region descriptors for review alongside the original CT series.
What is its most important limitation?Key limitation: ClearRead CT is an adjunct and must not be used without the original CT series. The cleared indication is for an asymptomatic population and requires both lungs in the field of view; radiologist judgment remains required.
Clinical takeaway. Clinical role: ClearRead CT is a post-processing adjunct for detecting pulmonary nodules on chest CT in an asymptomatic population; it generates a secondary vessel-suppressed lung CT with CADe marks and region descriptors and must be reviewed with the original CT series.
Evidence takeaway. Evidence from the reviewed source record: The FDA package documents software verification and the adjunctive vessel-suppression and CADe workflow; no exact-version independent clinical-outcome claim was promoted.
Evidence context: questions, not a score
Agent transcription of regulatory evidence context, not independent validation, clinical acceptance or a product recommendation. Separate studies and outcomes are not a leaderboard.
Existing study anchor: K161201 FDA evidence package for ClearRead CT. Tested version label: ClearRead CT.
What was tested?
A reader study measured localization ROC area and interpretation time with ClearRead CT versus unaided interpretation.
Source section: 510(k) summary, Testing Summary
On which cases and versions?
The K161201 summary does not report the reader-study sample size, site count or detailed composition. The existing study anchor is the exact FDA submission, not an independently verified commercial release.
Source section: 510(k) summary, Testing Summary
What changed?
The summary reports a statistically significant increase in localization ROC area and reduced reading time, without numeric effect sizes or confidence intervals in the reviewed text.
Source section: 510(k) summary, Testing Summary
What does this not establish?
The summary does not establish patient outcomes, downstream work-up burden, local workflow savings or performance for another release. Unreported denominators and confidence intervals remain unknown.
Source section: 510(k) summary, Testing Summary
Study design, population and missing context
evidence Role
Multi-reader multi-case reader validation and software verification.
reader study · 510(k) summary, Testing Summary
design
Reader study comparing use of ClearRead CT with unaided interpretation.
reader study · 510(k) summary, Testing Summary
setting
Not established: The reviewed regulatory summary does not establish this field for this study context.
training Population
Not established: The reviewed regulatory summary does not establish this field for this study context.
evaluation Population
CT chest examinations used in the reader validation; the summary does not state the number of cases.
reader study · 510(k) summary, Testing Summary
reference Standard
Not established: The reviewed regulatory summary does not establish this field for this study context.
comparator
The same task with ClearRead CT versus unaided interpretation.
reader study · 510(k) summary, Testing Summary
sites
Not established: The reviewed regulatory summary does not establish this field for this study context.
scanner Protocol
Not established: The reviewed regulatory summary does not establish this field for this study context.
sample Composition
Not established: The reviewed regulatory summary does not establish this field for this study context.
sponsor Involvement
Manufacturer-prepared regulatory summary submitted by Riverain. Independent-investigator status is not established.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Not established: No numerical age bound or explicit all-ages statement in the reviewed labeling sections. Study ages do not establish authorized age limits.
Documented care setting
Not established: No explicit constraint transcribed from the reviewed labeling sections. Unknown does not mean unrestricted.
ClearRead CT is a post-processing adjunct for detecting pulmonary nodules on chest CT in an asymptomatic population; it generates a secondary vessel-suppressed lung CT with CADe marks and region descriptors and must be reviewed with the original CT series.
ClearRead CT is an adjunct and must not be used without the original CT series. The cleared indication is for an asymptomatic population and requires both lungs in the field of view; radiologist judgment remains required.
The FDA package documents software verification and the adjunctive vessel-suppression and CADe workflow; no exact-version independent clinical-outcome claim was promoted.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The FDA package documents software verification and the adjunctive vessel-suppression and CADe workflow; no exact-version independent clinical-outcome claim was promoted.
No single product-level sensitivity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No single product-level specificity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K161201 FDA evidence package for ClearRead CT
DesignFDA 510(k) verification and validation evidence described in the exact submission
PopulationChest/lungs
Scopeexact submission
Tested versionClearRead CT
IndependenceSponsor or vendor study
K161201
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Previously acquired chest CT studies with both lungs in the field of view.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes CT post-processing and secondary-series output; exact DICOM routing, archive behavior, and local worklist integration require testing.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact installed deployment, hosting, service, and operational boundary is not established by the reviewed public FDA material.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: A secondary vessel-suppressed lung CT with CADe marks and region descriptors for review alongside the original CT series.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A secondary vessel-suppressed lung CT with CADe marks and region descriptors for review alongside the original CT series.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA package describes CT post-processing and secondary-series output; exact DICOM routing, archive behavior, and local worklist integration require testing.
Monitor K161201 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: ClearRead CT is an adjunct and must not be used without the original CT series. The cleared indication is for an asymptomatic population and requires both lungs in the field of view; radiologist judgment remains required.
The FDA package describes CT post-processing and secondary-series output; exact DICOM routing, archive behavior, and local worklist integration require testing.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. ClearRead CT is an adjunct and must not be used without the original CT series. The cleared indication is for an asymptomatic population and requires both lungs in the field of view; radiologist judgment remains required.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price or product-specific reimbursement was established in the reviewed public material.
Monitor K161201 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: ClearRead CT is an adjunct and must not be used without the original CT series. The cleared indication is for an asymptomatic population and requires both lungs in the field of view; radiologist judgment remains required.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-04Last searched
25Fields reviewed
11Source classes checked
0Screened PubMed leads
2Screened trial leads
0Unreviewed FDA recall leads
Screened two trial records. NCT02440139 is manufacturer-scoped to Riverain lung-nodule software but does not identify ClearRead CT, K161201, or a tested version; NCT06514248 is a different vendor, so both are quarantined. The current discovery snapshot contains 0 PubMed and 2 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Care setting: Not publicly available - checked 2026-11-12 - Exact FDA submission
The K161201 Indications for Use and 510(k) summary do not state a care setting. Unknown does not mean unrestricted.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared product version was established. Obtain a written quote separating license, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact installed deployment, hosting, service, and operational boundary is not established by the reviewed public FDA material.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
The FDA decision material does not establish the complete security posture for the exact product and deployment. Obtain architecture, identity, audit, encryption, retention, support-access, vulnerability-management, and incident-response evidence.
Installation timeline: Not yet reviewed
Training: Not publicly available - checked 2026-11-12 - Exact FDA submission
The K161201 FDA material names the radiologist as the user but states no training, qualification, or competency requirement. Obtain onboarding and competency documentation for the exact release from the vendor.
Authorized purpose: Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
Authorized purpose: Characterization and relative cancer-risk assessment of incidentally detected pulmonary nodules 6-15 mm in adults, with use as one input to follow-up and clinical decision-making under published guidelines; not lung-cancer screening
Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
2026-11-09 · workflow.navigationRole · Added the documented interpretation role for the ClearRead CT navigation pilot. Original CT images remain required; vessel-suppression output does not establish autonomous use. Reviewer: agent / c07-original-label-review. Live publication not verified.